论文部分内容阅读
目的:研究人脑胶质瘤中bcl-2蛋白表达强度与胶质瘤的临床病理分级及患者预后间的关系。方法:应用免疫组化技术检测58例脑胶质瘤患者手术切除标本中bcl-2蛋白表达强度、HE染色确定肿瘤病理分级、门诊及电话随访,掌握患者术后生存时间。结果:bcl-2蛋白表达强度与肿瘤病理分级相关(P<0.01)、与患者术后生存时间相关(P<0.01)。bcl-2蛋白表达愈强,胶质瘤临床病理分级愈高、患者术后生存时间也愈短。结论:bcl-2蛋白表达水平与胶质瘤恶性程度成正比、与胶质瘤患者术后生存时间成反比,是评价胶质瘤恶性程度和预后的客观指标之一。
Objective: To study the relationship between the expression of bcl-2 protein in human glioma and the clinicopathological grade of glioma and the prognosis of patients. Methods: Immunohistochemical technique was used to detect the expression of bcl-2 protein in 58 cases of gliomas. HE staining was used to determine the pathological grading, outpatients and telephone follow-up, and the postoperative survival time was determined. Results: The expression of bcl-2 protein was correlated with tumor grade (P <0.01), and correlated with postoperative survival time (P <0.01). The stronger the expression of bcl-2 protein, the higher the clinicopathological grade of glioma, the shorter the survival time of patients. Conclusion: The expression of bcl-2 protein is proportional to the malignant degree of glioma and is inversely proportional to the survival time of glioma patients. It is one of the objective indexes to evaluate the malignant degree and prognosis of glioma.